On March 28, 2022 ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "ImmuneOnco") reported that data from 2 different new projects in two posters will be presented at the 2022 annual meeting of American Association for Cancer Research (AACR) (Free AACR Whitepaper) hold in New Orleans from April 8 to 13 (Press release, ImmuneOnco Biopharma, MAR 28, 2022, View Source [SID1234655644]). Two abstracts from ImmuneOnco were selected for poster presentation at the AACR (Free AACR Whitepaper) 2022. These posters will summarize the progress of the company’s early clinical and preclinical pipelines like IMM2902.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Wenzhi Tian, founder, chairman and CEO of ImmuneOnco, said: "The data we present at AACR (Free AACR Whitepaper) 2022 will provide insight into the targets related to our 3 pipelines and promising data to support further clinical development. These study data have played a critical role in guiding our clinical development program. We are excited to have the opportunity to share these data with our colleagues in the oncology field.